Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy

被引：1
|
作者：
Jensen, B. V.
Schou, J. V.
Johannesen, H. H.
Christensen, I. J.
Nielsen, D.
Johansen, J. S.
Hogdall, E. V.
Larsen, O.
Yilmaz, M.
Pfeiffer, P.
机构：
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Copenhagen, Herlev Hosp, Dept Radiol, DK-2730 Herlev, Denmark
[4] Univ Copenhagen, Finsen Inst, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[6] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark
[7] Aalborg Hosp, Dept Oncol, Aalborg, Denmark
[8] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3573
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
    Fornaro, Lorenzo
    Baldi, Giacomo Giulio
    Masi, Gianluca
    Allegrini, Giacomo
    Loupakis, Fotios
    Vasile, Enrico
    Cupini, Samanta
    Stasi, Irene
    Salvatore, Lisa
    Cremolini, Chiara
    Vincenzi, Bruno
    Santini, Daniele
    Tonini, Giuseppe
    Graziano, Francesco
    Ruzzo, Annamaria
    Canestrari, Emanuele
    Magnani, Mauro
    Falcone, Alfredo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (03) : 243 - 251
  • [32] CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-RESISTANT ELDERLY METASTATIC COLORECTAL CANCER PATIENTS: CLINICAL OUTCOME ACCORDING TO KRAS AND BRAF MUTATIONAL STATUS
    Baldi, G.
    Fornaro, L.
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Cupini, S.
    Allegrini, G.
    Marcucci, L.
    Stasi, I
    Santini, D.
    Tonini, G.
    Graziano, F.
    Ruzzo, A.
    Magnani, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 77 - 77
  • [33] KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer
    Cabart, Mathilde
    Frenel, Jean-Sebastien
    Campion, Loic
    Ramee, Jean-Francois
    Dupuis, Olivier
    Senellart, Helene
    Hiret, Sandrine
    Douillard, Jean-Yves
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2016, 103 (06) : 541 - 551
  • [34] EFFICACY AND SAFETY OF CETUXIMAB PLUS IRINOTECAN IN IRINOTECAN-REFRACTORY ELDERLY PATIENTS (>65 YEARS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 195 - 195
  • [35] LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan
    Fakhr, Elham
    Zare, Fatemeh
    Azadmanesh, Kayhan
    Teimoori-Toolabi, Ladan
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 143
  • [36] Efficacy and safety of Cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    ONKOLOGIE, 2010, 33 : 174 - 174
  • [37] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [38] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [39] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [40] Patterns of use and outcomes with irinotecan and oxaliplatin in the treatment of 5-fluorouracil (5-FU) refractory metastatic colorectal cancer: An Australian population based analysis.
    Damianovich, D.
    Adena, M.
    Tebbutt, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 178S - 178S
12345